Form 4: Werewolf Therapeutics 10% Owner Sells Shares

A 10% owner and director of Werewolf Therapeutics, Inc. reported the sale of over 213,000 shares of common stock through pre-arranged trading plans.

Summary

• Ansbert Gadicke, a director and 10% owner of Werewolf Therapeutics, Inc. (HOWL), reported multiple sales of common stock.
• The transactions were executed under a Rule 10b5-1 trading plan established on September 24, 2025.
• A total of 213,529 shares were sold across four separate dates in November 2025.
• On November 7, 2025, 68,480 shares were sold at a weighted average price of $1.11.
• On November 10, 2025, 48,570 shares were sold at a weighted average price of $1.18.
• On November 11, 2025, 55,810 shares were sold at a weighted average price of $1.14.
• On November 12, 2025, 40,669 shares were sold at a weighted average price of $1.09.
• Following these transactions, the reporting persons collectively beneficially own 5,691,191 shares indirectly.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to significant insider selling by a 10% owner and director, even though it was pre-scheduled. While Rule 10b5-1 plans mitigate the immediate negative inference, the consistent selling at these price levels by a major stakeholder can still be viewed unfavorably by the market.

Negatives

• A significant number of shares (213,529) were sold by a director and 10% owner, which can be interpreted as a lack of confidence in the company's near-term prospects.
• The sales occurred at relatively low price points, ranging from $1.09 to $1.18 per share.

Risks

• Insider selling, even if pre-scheduled, can signal to the market that those closest to the company may perceive limited upside or potential challenges ahead.
• The sales could put downward pressure on the stock price, especially if interpreted negatively by other investors.

Future Outlook

NA

Industry Context

This filing reflects routine insider trading activity under a pre-established plan, common in the biotechnology sector for liquidity management by significant shareholders. While the sales are by a 10% owner, the context of a Rule 10b5-1 plan suggests a pre-determined schedule rather than an immediate reaction to new information, which is a common practice among executives and large shareholders in the biotech industry to manage personal finances and diversify holdings.

Related Party Transactions

• Ansbert Gadicke, a director and 10% owner, along with several entities he controls (MPM BioImpact LLC, MPM Oncology Innovations Fund LP, UBS Oncology Impact Fund L.P., etc.), engaged in sales of Werewolf Therapeutics common stock.
• These transactions are considered related-party dealings due to the reporting person's significant influence and ownership stake.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to decreased confidence and downward pressure on the stock price.
• Employees: No direct impact mentioned, but a declining stock price could affect equity-based compensation.

Key Dates

Recommendation

While the insider selling by a 10% owner and director is a negative signal, the transactions were executed under a pre-established Rule 10b5-1 plan, which suggests a planned diversification or liquidity event rather than an immediate reaction to adverse news. Given the lack of other specific financial or operational updates in this Form 4, a 'hold' recommendation is appropriate. Investors should monitor future filings and company performance for more comprehensive insights before making a definitive 'buy' or 'sell' decision.

Keywords

Werewolf Therapeutics, HOWL, SEC Form 4, Insider Selling, Stock Sale, Beneficial Ownership, Rule 10b5-1, Ansbert Gadicke, MPM BioImpact, Biotechnology, Pharmaceuticals